参麦注射液联合化疗治疗中晚期恶性肿瘤的临床效果及安全性

Clinical efficacy and safety of Shenmai Injection combined with chemotherapy in the treatment of advanced malignant tumors

目的研究中晚期恶性肿瘤应用参麦注射液联合化疗方案的效果及不良反应发生率。方法选取2017年8月至2019年8月河南省商丘市第四人民医院住院治疗的98例中晚期恶性肿瘤患者作为研究对象,按照随机数字表法分为参照组和试验组,每组49例。参照组采用化疗治疗,试验组采用参麦注射液联合化疗治疗,比较两组患者临床疗效、不良反应发生率、T淋巴细胞亚群、相关细胞因子水平、肿瘤标志物水平。结果试验组临床总有效率高于参照组,差异有统计学意义(P<0.05);试验组不良反应总发生率低于参照组,差异有统计学意义(P<0.05);治疗后试验组CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)比值均高于参照组,CD8^(+)水平低于参照组,差异有统计学意义(P<0.05);治疗后试验组白介素-6(IL-6)、白介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平均低于参照组,差异有统计学意义(P<0.05);治疗后试验组癌胚抗原(CEA)、糖类抗原153(CA153)、组织多肽特异性抗原(TPS)水平均低于参照组,差异有统计学意义(P<0.05)。结论参麦注射液联合化疗可有效控制中晚期恶性肿瘤患者疾病进展,减少不良反应,且能够更好地改善机体免疫功能、炎症因子水平以及肿瘤标志物水平,值得借鉴。

Objective To study the effect of Shenmai Injection combined with chemotherapy regimen and the incidence of adverse reactions in advanced malignant tumors.Methods A total of 98 patients with advanced malignant tumors who were hospitalized in the Fourth People's Hospital of Shangqiu City from August 2017 to August 2019 were selected as research objects,they were divided into reference group and experimental group according to random number table method,with 49 cases in each group.The reference group was treated with chemotherapy,the experimental group received Shenmai Injection combined with chemotherapy,and the clinical efficacy,incidence of adverse reactions,T lymphocyte subsets,related cytokine levels and tumor marker levels were compared between the two groups.Results The total clinical effective rate(79.59%)in the experimental group was higher than that in the reference group(44.90%),and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the experimental group(6.12%)was lower than that in the reference group(30.61%),the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)ratio in the experimental group were higher than those in the reference group,and the level of CD8^(+)was lower than that in the reference group,the differences were statistically significant(P<0.05).After treatment,the levels of interleukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in the experimental group were lower than those in the reference group,and the differences were statistically significant.After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153)and tissue polypeptide specific antigen(TPS)in the experimental group were lower than those in the reference group,and the differences were statistically significant(P<0.05).Conclusion Shenmai Injection combined with chemotherapy can effectively control the disease progression of patients with advanced malignant tumors,reduce adverse reactions,and can better improve the immune function,inflammatory factor levels and tumor marker levels,which is worth of learning.